ACRS — Aclaris Therapeutics, Inc. Dilution Risk Tracker

Aclaris Therapeutics, Inc. (ACRS) has a DilutionScore of 50/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

Cash runway is a key watch item: ACRS has approximately 4 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for ACRS in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for ACRS alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.